As per Future Market Insights’ latest industry analysis, valuation of the global Cell Therapy Manufacturing Market was around US$ 3.3 Bn in 2021, and is projected to exhibit a CAGR of close to 14.2% over the forecast period. The market is expected to reach US$ 13.9 Bn in 2032.
Cell therapies are utilised widely to treat viral infections, cancer, hemoglobinopathies, and hereditary immunological disorders. Introduction of reagents and closed system automated equipment for the manufacturing of cellular therapies is an outcome of the increasing research activities in the field of such therapies.
Get a Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15536
A decentralised manufacturing model for clinical trials in cell therapies involving multiple sites is gaining popularity around the world. Such cases advocate for the treatment of patients with cells generated by automated equipment at each participating centre using a single, centrally held investigational new drug application (IND).
Many academic institutions are now investing in the development of such automated devices for point-of-care manufacturing and participation in multi-center decentralised clinical trials. As a result, the global cell therapy manufacturing market is expected to boom over the next decade. Furthermore, the introduction of novel therapies approved by regulatory bodies for targeted therapeutic approaches would propel the market’s overall growth during the forecast period.
Key Takeaways from Market Study
- According to one source, the autologous segment will account for approximately 56.0% of the global market in 2021.
- The cancer indication held nearly 31.0% of the cell therapy manufacturing market in 2021.
- In terms of purpose, the clinical segment is expected to account for approximately 42.0% of the global market share in 2021.
- In 2021, the injectable route of administration of cell therapies will account for approximately 44.0% of the global market.
- In 2021, the hematopoietic stem cells (HSC) segment held a 25.0% share of the global cell therapy manufacturing market.
- The hospital settings category accounted for approximately 38.1% of the global cell therapy manufacturing market in 2021.
- China held a share of around 38.2% in 2021 in the East Asia cell therapy manufacturing market.
“Increasing number of research activities by key companies to reduce risks and get ready for a highly productive future are anticipated to drive the market. Besides, they are striving to develop innovative technologies that can assist investigators in automating their processes for gaining success in future,” says an analyst of Future Market Insights.
Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-15536
Competitive Landscape: Cell Therapy Manufacturing Market
Key players in the cell therapy manufacturing market are focusing on R&D activities to initiate regenerative medicine manufacturing. Moreover, they are promoting commercial manufacturing for their clients by offering novel solutions to cell therapy developers.
For instance,
- In March 2022, Thermo Fisher Scientific presented a new large-volume electroporation system, the purpose of which is to simplify cell therapy development. The company aims to simplify transition from clinical development to commercial manufacturing among cell therapy developers.
- Charles River Laboratories’ Memphis plant became the first CDMO in North America to manufacture commercial allogeneic cell therapies after receiving European Medicines Agency (EMA) approval in August 2022.
Get Exclusive Insights on Cell Therapy Manufacturing Market
Future Market Insights offers a unique perspective and actionable insights on the cell therapy manufacturing market in its latest study, presenting a historical demand assessment of 2012 – 2021 and projections for 2022 – 2032. The global cell therapy manufacturing market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
Key Players:
- Merck KGaA
- Avantor, Inc.
- Cell Therapies Pty Ltd
- Thermo Fisher Scientific
- Charles River Laboratories
- Catalent, Inc
- Bio-Techne
- Cytiva
- Lonza
- The Discovery Labs
- BIOCENTRIQ
- FUJIFILM Diosynth Biotechnologies
- Novartis AG
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- WuXi AppTec.
- OXGENE
- Pharmaron
- Aldevron
- FLODESIGN SONICS
- Exothera
Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-15536
Key Segments Covered in Cell Therapy Manufacturing Industry
By Source:
- Autologous
- Allogenic
By Indication:
- HIV
- Autoimmune Disorders
- Immune Deficiencies
- Cancer
- Neurological Disorders
By Manufacturing Purpose:
- Clinical
- Commercial
- Pre-clinical
By Route of Administration:
- Topical
- Injectable
- Infusion
- Implantable Bio-Scaffold
By Cell Type:
- Hematopoietic (Blood-Forming) Stem Cells (HSC)
- Skeletal Muscle Stem Cells
- Mesenchymal Stem Cells
- Lymphocytes
- Dendritic Cells
- Pancreatic Islet Cells
- CAR-T Cells
By End User:
- Hospital Settings
- Intensive Outpatient Treatment Centers
- Academic and Research Institutes
- Specialty Clinics
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs